OncoMatch/Clinical Trials/NCT05355051
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
Is NCT05355051 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Azacytidine and Pembrolizumab for hodgkin's lymphoma.
Treatment: Azacytidine · Pembrolizumab — This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Performance status
ECOG/LANSKY 0–2
ECOG performance status =< 3 or Lansky performance status >= 50
Prior therapy
Must have received: — relapsed/refractory
HL patients with relapse or progression
Lab requirements
Kidney function
Adequate renal function per age unless related to the disease
Liver function
Total bilirubin < 2 x ULN unless increase is due to Gilbert's disease; AST < 3 x ULN unless considered due to lymphoma involvement
Adequate renal function per age unless related to the disease; Total bilirubin < 2 x ULN unless increase is due to Gilbert's disease; AST < 3 x ULN unless considered due to lymphoma involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify